natgillin/translations-raw huggingface dataset:
Process according to any one of claims 1 to 11, characterized in that the base is a hydroxide, a carbonate or a bicarbonate, in particular an alkali hydroxide, an alkali carbonate or an alkali bicarbonate, in particular sodium hydroxide, sodium carbonate or sodium bicarbonate. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 11, naznačen time, da je baza hidroksid, karbonat ili bikarbonat, naročito alkalijski hidroksid, alkalni karbonat ili alkalni bikarbonat, naročito natrijev hidroksid, natrijev karbonat ili natrijev bikarbonat.
Example 1: Generation of the expression plasmids 
Broj objave europskog patenta:
The composition according to claim 10, wherein the inhibitor of an endocannabinoid-degrading enzyme is selected from the group consisting of JZL184 and URB597. 
Pripravak u skladu s patentnim zahtjevom 10, naznačen time što se inhibitor enzima koji razgrađuje endokanabinoide bira iz skupine koju čine IZL184 i URB597.
The compound according to claim 1, wherein R3 represents a 5 or 6 membered heterocycloalkyl or the group —CHR5R6 wherein R5 represents hydrogen or C1-3alkyl and R6 represents 5 or 6 membered heterocycloalkyl, wherein said heterocycloalkyl is optionally substituted with C1-3alkyl or —COCH3. The compound according to claim 3, wherein R6 is: 
Spoj u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, naznačen time što R3 predstavlja 5 ili 6-eročlani heterocikloalkil ili skupina -CHR5R6, gdje R5 predstavlja vodik ili C1-3alkil, a R6 predstavlja 5 ili 6-eročlani heterocikloalkil, gdje navedeni heterocikloalkil može biti izborno supstitiran s C1-3alkilom ili -COCH3.
In another embodiment, an aforementioned method is provided wherein the water soluble polymer is PSA. In another embodinment the PSA is comprised of about 10 - 300 sialic acid units. 
Postupak prema zahtjevu 2, pri čemu je polimer topljiv u vodi PSA i sadržan je od oko 10 - 300 jedinica sijalinske kiseline.
the compound of formula VI is not isolated; or 
(c) spoj s formulom VI nije izoliran; ili
Before receiving the handover request Ack from the target eNB, the SGW sends the user data packets to the source eNB, and the source eNB forwards user data packets delivered by the SGW to the UE. 
Postupak prema bilo kojem zahtjevu od 1 do 3, naznačen time da, kada target eNB prosljeđuje pakete korisničkih podataka isporučene od SGW prema UE nakon prijema posebnog paketa podataka od izvorišnog eNB, ciljni eNB ne prosljeđuje poseban paket podataka prema UE.
The process of claim 5, wherein, the organic acid solution in said step b) is selected from the group consisting of oxalic acid, formic acid, acetic acid, and propionic acid. 
Postupak u skladu s patentnim zahtjevom 5, naznačen time što se kiselinu u otopini organske kiseline u navedenom koraku 2) bira između oksalne kiseline, mravlje kiseline, octene kiseline ili propionske kiseline.
This results in 6.6 g of a reaction crude containing a mixture of diastereoisomers in a proportion of 65% of (4) and 35% of (4bis). 
Iz toga se dobije 6,6 g sirovog proizvoda koji sadrži smjesu diastereoizomera u omjeru od 65% (4) i 35% (4bis).
The humanized CD37-specific binding protein or the CD20-specific binding protein or the article of manufacture for use in treating a B-cell cancer or an autoimmune disease of any one of the preceding claims, wherein the CD20-specific monoclonal antibody is Rituximab. 
Humanizirani protein koji se specifično veže na CD37, ili protein koji se specifično veže na CD20, ili proizvodni artikl za upotrebu u liječenju karcinoma B-stanica ili autoimune bolesti, navedeni u bilo kojem od prethodnih patentnih zahtjeva, pri čemu je CD20-specifično monoklonsko antitijelo Rituximab.
The compound according to item-2 wherein A is selected from the group consisting of 
Rc 1 Rp su neovisno odabrani iz skupine koja se sastoji od vodika i alkila.
The immunogenic composition of paragraph 62 wherein the Hib conjugate is present in a lower dose than the dose of each of the at least two further bacterial saccharide conjugates. 
Imunogeni pripravak u skladu s patentnim zahtjevom 1, naznačen time što konjugat Hib je prisutan u manjoj dozi saharida od doze saharida za svaki od najmanje dva dodatna konjugata bakterijskih saharida.
the compound of any one of clauses (1)-(14) wherein A15 is selected from: 
Kompozicija bilo kojeg patentnog zahtjeva 1 do 9, gdje (1) je spoj formule:
A composition that can suitably be used as an additive in beverages and foodstuffs, which composition: contains at least 0.5%, preferably at least 1.0%, by weight of dry matter, of pyrazine derivatives according to formula (I): wherein R1 - R4 independently represent hydrogen; a hydroxyhydrocarbyl residue; an ester of a hydroxyhydrocarbyl residue; or an ether of a hydroxyhydrocarbyl residue; and at least one of R1- R4 is a hydroxyhydrocarbyl residue or an ester or an ether thereof; and 
HR P20070273 T3 PATENTNI ZAHTJEVI Pripravak koji se može prikladno upotrijebiti kao aditiv u pićima i prehrambenim proizvodima, naznačen time, što: i. > sadržava najmanje 0,5%, poželjno najmanje 1,0%, po masi suhe tvari, derivata pirazina prema formuli (T):
Polypeptide, protein or construct according to claim 9, in which at least one (and up to all) of the immunoglobulin single variable domain or Nanobody directed against c-met comprises two disulphide bridges. 
Polipeptid, protein ili konstrukt prema patentnom zahtjevu 8, naznačeni time što najmanje jedna imunoglobulinska pojedinačna varijabilna domena koja je usmjerena protiv c-met sadrži dva disulfidna mosta.
Rb represents a -Y-aryl or-Z-heterocyclyl group wherein said aryl and heterocyclyl groups may be optionally substituted by one or more (e.g. 
Rb predstavlja Y-aril ili Z-heterociklil grupu pri čemu navedene aril i heterociklil grupe mogu biti opcionalno supstituirane jednom ili više (npr.
A process as in Claim 16, wherein the compound of formula (XI-S) is reacted with the compound of formula (VI-B) at a temperature of about 5°C. 
Postupak kao u Zahtjevu 16, pri čemu spoje formule (XI-S) reagira sa spojem formule (VI-B) na temperaturi pri oko 5°C.
Preferred among the various disclosed concentration ranges is a concentration of 300 U/mL. Further the aqueous pharmaceutical formulation also can comprise zinc, m-cresol, glycerol, polysorbate 20 and sodium and mixtures thereof in the ranges disclosed herein in relation to the aqueous pharmaceutical formulation of the present invention. In a preferred embodiment the aqueous pharmaceutical formulation also comprises 0.1 µg to 10 µg lixisenatide per U insulin glargine. 
Vodena formulacija namijenjena upotrebi u skladu s patentnim zahtjevom 15, naznačena time što navedeni farmaceutski pripravak dodatno sadrži pomoćne tvari, koje se bira iz skupine koju čine cink, m-krezol, glicerol, polisorbat 20 i natrij. Vodena formulacija namijenjena upotrebi u skladu s patentnim zahtjevom 15, naznačena time što navedeni farmaceutski pripravak dodatno sadrži 0,1 ug do 10 ug liksisenatida po jedinici inzulin glargina.
The method as recited in Clause 16 wherein said VMAT2-mediated disorder is a chronic hyperkinetic movement disorder. 
D Bi D ili njegova sol, naznačen time da je za uporabu za liječenje kroničnog poremećaja hiperkinetičkog pokreta.
Transfer apparatus according to any of claims 4-6, wherein the pivoting axis is perpendicular to a main direction of the first profile and the gripper can be tilted by slowing down one of the first and second steering members with respect to another of the first and second steering members. 
Prijenosni uređaj prema bilo kojem zahtjevu 1.-5., naznačen time da su prva i druga površina (12, 13) smještene na suprotnim stranama tračnice. Prijenosni uređaj prema bilo kojem zahtjevu 1.-6., naznačen time da su prvi i drugi zahvatni član (14, 15) smješteni izvan područja okruženog beskonačnom stazom (4) i treći zahvatni član (16) je smješten unutar rečenog područja.
According to the present invention, the at least one of the two images is a rotated image over an angle in the range from about 4.5° to about 7.5°, preferably over an angle of about 6°. 
Identifikacijski dokument (1) prema zahtjevu 3 ili 4, gdje je najmanje jedna od dvije slike rotirana slika duž kuta u opsegu od oko -4,5* do približno oko -7,5*, prvenstveno duž kuta od oko -6".
In some instances it can be beneficial to include the presence of a Lewis acid, for example, AlCl3, ZnBr2, and the like, in a suitable solvent, such as, DMF and the like. 
U nekim slučajevima može biti povoljno uključiti prisutnost Lewis-ove kiseline, na primjer AICl3, ZnBr,, te slično, u prikladnom otapalu, poput, na primjer, DMF i slično.
Vaccine comprising at least two fragments of Proprotein convertase subtilisin/kexin type 9 (PCSK9), wherein at least one fragment of said at least two fragments comprises at least 8 consecutive amino acid residues of amino acid residues 150 to 170 of PCSK9 according to SEQ ID No. 9 and wherein at least one fragment of said at least two fragments comprises at least 8 consecutive amino acid residues 205 to 225 of PCSK9 according to SEQ ID No. 9. 
Cjepivo, naznačeno time, da obuhvaća najmanje dva fragmenta proproteinske konvertaze subtilizin/keksin tipa 9 (PCSK9), pri čemu barem jedan od navedena najmanje dva fragmenta sadrže najmanje devet uzastopnih aminokiselinskih ostataka od aminokiselinskih ostataka 153 do 165 od PCSK9 u skladu sa SEQ ID NO:9, i gdje barem jedan od navedena najmanje dva fragmenta sadrži najmanje devet uzastopnih aminokiselinskih ostataka od aminokiselinskih ostataka 209 do 222 od PCSK9 u skladu sa SEQ ID NO:9.
The buffer system is present at a concentration of between 5 and 14 mM, most suitably about 10 mM. 
ili nije slobodan od fosfatnih pufera ili sadrži sustav fosfatnog pufera u koncentraciji najviše 0,1 mM.
where alkyl is substituted by 1 to 2 substituents independently of one another selected from the group consisting of hydroxy and C1-C4-alkoxy and 
R' predstavlja C;-Cs-alkil ili C2-Cs-cikloalkil, gdje alkil je supstituiran s 1 do 2 supstituenta koji su međusobno neovisno odabrani iz skupine koja sadrži hidroksi i Cy-Cu-alkoksi i
More preferably in the range of 0.3 to 200 nmol/ml, 3 to 180 nmol/ml, 10 to 150 nmol/ml or 30 to 120 nmol/ml. 
Sastav u skladu sa bilo kojim prethodnim zahtjevom, naznačen time, što svaki polipeptid ima koncentraciju u rasponu od 0.03 do 200 nmol/ml, 0.3 do 200 nmol/ml ili 30 do 120 nmol/ml.
a housing having an interior; a cable spool positioned within the interior of the housing, wherein the cable spool rotates about an axis relative to the housing to allow the first portion of the fiber optic cable to be paid out from the interior of the housing; 
Postupak izvlačenja optičkog kabela odmotavanjem (22, 122) iz kutije sa optičkim kabelom prema Zahtjevu 7, gdje igla ili klin fiksiraju položaj kalema (37, 137) kabela u odnosu na kućište (23, 123).
Inhibitory effect on drug-induced tremor in mice is a good indication of muscle relaxant efficacy of compounds in humans. 
Inhibitorski učinak na tremor izazvan s lijekom u miševima je dobra indikacija učinkovitosti spoja kao relaksanta mišića u ljudima.
A pharmaceutical combination of Claim 28 wherein the sulfonyl ureas are selected from glyburide, glibenclamide, glimepiride, glipizide, gliclazide, chlorpropamide, other known sulfonylureas or other antihyperglycemic agents which act on the ATP-dependent channel of the beta-cells. 
Farmaceutski sastav Zahtjeva 28, naznačen time, da su sulfonil uree odabrane od gliburida, glibenklamida, glimepirida, glipizida, gliklazida, klorpropamida i drugih poznatih sulfonilurea ili sredstva protiv glikemije koji djeluju na ATP-ovisni kanal beta stanica.
(in the formula, Ts represents p-toluenesulfonyl, Ph represents phenyl, and R1 represents lower alkyl); or 
(u formuli Ts predstavlja p-toluensulfonil, Ph predstavlja fenil, a R' predstavlja nerazgranati ili razgranati C,.salkil); ili
wherein the second plurality of resource sets comprises a plurality of cells, the control channel search spaces being distributed over the cells, and wherein the secondary station determines from the presence of the control channel in a specific cell the indication of the particular resource set within which the allocated resource is located. 
Metoda iz bilo kojeg od prethodnih patentnih zahtjeva, gdje veliki broj skupova resursa sadrži veliki broj ćelija, pri čemu su prostori za pretragu kontrolnog kanala distribuirani preko ćelija, i gdje sekundarna stanica (110) određuje iz mapiranja i prisustva kontrolnog kanala u specifičnoj ćeliji indikaciju skupa resursa u okviru kojeg je alocirani resurs smješten.
The coating composition according to claim 15, wherein the curing agent is an epoxy functional compound, a phenolic functional crosslinker, a hydroxyl functional crosslinker, an amine functional crosslinker, a carboxylate functional crosslinker, or an isocyanate functional crosslinker. The coating composition according to claim 16, wherein the curing agent is (1) an amino compound that is hexamethoxymethylmelamine, or (2) an epoxyfunctional compound that is bisphenol-A-diglycidyl ether or triglycidylisocyanurate. 
Sastav premaza prema zahtjevu & ili 9, naznačen time, da sredstvo za umreživanje je amino spoj, npr. heksametoksimetilolmelamin, spoj s epoksi funkcionalnom skupinom, npr. bis-fenol-A-diglicidil eter ili triglicidilizocijanurat, ili sredstvo za umreživanje s fenolnim, hidroksilnim, amino, karboksilatni, ili izocijanatnim funkcionalnim skupinama.
wherein, the bonding material non-removably secures the fitment to the interior passage of the neck of the container and thereby renders the product tamper-evident, characterized in that the bonding material includes a heat-activated ceramic or glass bonding compound, solder glass material and/or a ring of soda lime glass heat-bonded between the interior surface of the neck (24) of the container and the radially outer surface of the fitment (14). 
636): i vezivni materijal, koji se nalazi između unutarnje površine grla spremnika i radijalne vanjske površine nastavka. gdje vezivni materijal neuklonjivo osigurava nastavak na unutarnji prolaz grla spremnika i tako omogućuje da se vidi ako je na proizvodu došlo do neovlaštenog rukovanja, naznačen time što vezivni materijal uključuje toplinom aktivirani keramički ili stakleni vezivni spoj, lemljenje staklenog materijala 1/1li prstena od običnog stakla toplinski vezanog između unutarnje površine grla (24) spremnika i radijalne vanjske površine nastavka (14).
The torpedo of claim 1, wherein the expulsion of reinstatement materials from the internal chamber is enabled by a hydraulic ram and a plunger. 
Torpedo prema zahtjevu 1, naznačen time da se izbacivanje materijala za rekonstrukciju iz unutarnje komore omogućava pomoću hidrauličkog nabijača (91) i klipa (33).
The method of claims 12 or 13 wherein said second protein of interest is a protein that imparts a beneficial property to proteins expressed by said cells, and wherein said protein that imparts a beneficial property is an anti-apoptotic protein; a protein that confers resistance to oxidative stress to a cell; a chaperone protein involved in facilitating protein folding; a protein involved in extracellular secretion of proteins; a glycolytic enzyme; a cell cycle regulation protein; a glycosylation enzyme; or any combination thereof. 
Postupak u skladu s patentnim zahtjevom 12 ili 13, naznačen time, da je spomenuti drugi protein od interesa protein koji prenosi blagotvorno svojstvo na proteine koje eksprimiraju spomenute stanice, pri čemu je spomenuti protein koji prenosi blagotvorno svojstvo anti-apoptotični protein; protein koji utječe na to, da je stanica otporna na oksidativni stres; šaperon koji olakšava savijanje proteina; protein koji je uključen u izvanstaničnu sekreciju proteina; glukolitički enzim; protein koji regulira stanični ciklus; enzim glikozilacije, ili njihova kombinacija.
Antagonists do not diminish the baseline intracellular response in the absence of an agonist or partial agonist. 
Antagonisti ne umanjuju osnovni intracelularni odgovor u odsutnosti agonista ili dijela agonista.
Y' is selected from -H, an oxo group, the linking group with the reactive group bonded thereto, an optionally substituted linear, branched or cyclic alkyl, alkenyl or alkynyl having from 1 to 10 carbon atoms, an optionally substituted 6- to 18-membered aryl, an optionally substituted 5- to 18-membered heteroaryl ring containing one or more heteroatoms independently selected from nitrogen, oxygen, and sulfur, an optionally substituted 3- to 18-membered heterocyclic ring having 1 to 6 heteroatoms; 
je Y' odabran od -H, okso skupine, vezujuće skupine na koju je vezana reaktivna skupina, izborno supstituiranog linearnog, razgranatog ili cikličnog alkila, alkenila ili alkinila koji ima od 1 do 11 ugljikovih atoma, izborno supstituiranog 6-članog do 18-članog arila, izborno supstituiranog 5-članog do 18-članog heteroarilnog prstena koji ima jedan ili više heteroatoma neovisno odabranih od dušika, kisika i sumpora i izborno supstituiranog 3- do 18-članog heterocikličnog prstena koji ima 1 do 6 heteroatoma;
The liquefied gas treatment system according to claim 1, wherein a gas component of the BOG, which is decompressed to a gas-liquid mixed state while passing through the decompressing means (22), is joined with the BOG which is discharged from the cargo tank (1;11) and supplied to the compressor (150;13). 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 1, naznačen time što se plinovitu komponentu vraćenu u skladišni spremnik (11) ispušta iz skladišnog spremnika zajedno s otparenim plinom nastalim u skladišnom spremniku, te šalje u kompresor (13,13a,13b).
A process for preparing a compound of formula I-a: wherein Ring A, Ring B and Y are as defined in 1, which comprises reducing a compound of formula III: wherein Ring A, Ring B and Y are as defined in 1, and R12 is a lower alkyl group. 
€ Riža gdje su Prsten A, Prsten B i Y definirani kao u patentnom zahtjevu 1, a R'* je atom broma ili atom joda, sa spojem boronske kiseline formule X:
Fig. 3 shows a sectional view of the packaging, 
Slika 3 prikazuje pogled na pakiranje u presjeku,
cooling the solution resulting from step (iii) to a temperature of 10°C; 
hlađenje otopine dobivene u koraku (ii) do temperature od;
A compound of formula (I), or stereoisomers or pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are 
Spoj, naznačen time, da ima formulu (1), ili njegovi stereoizomeri ili njegove farmaceutske prihvatljive soli, a2 R
The pharmaceutical composition according to claim 13, for use as a medicament. 
Lipidni sastav prema zahtjevu 27, za uporabu kao lijek.
The cytotoxic agent according to claim 8 or 9, wherein 3 to 4 DM1 molecules are conjugated to a single antibody molecule via SMCC. 
Citotoksično sredstvo u skladu s patentnim zahtjevom 6 ili 7, naznačeno time što su 3 do 4 molekule DM1 konjugirane s jednom molekulom protutijela preko SMCC.
determining the average gene copy number of the HER2 gene per tumour cell in a tumour sample obtained from the patient, wherein an average gene copy number of greater than or equal to 10 per tumour cell indicates that the cancer is susceptible to treatment with the specific binding member, optionally, wherein the method further comprises: 
(i) utvrđivanje prosječnog broja genskih kopija od HER2 po stanici tumora u tumorskom uzorku koji se dobije od pacijenta, pri čemu prosječan broj genskih kopija koji je veći od 10 ili je točno 10 po stanici tumora, pokazuje da rak ima sklonost na liječenje sa specifičnim veznim elementom, opcijski, gdje postupak nadalje obuhvaća:
In order to prolong here the open time in a simple and effective manner, according to one embodiment of the present invention, it is provided that the adhesion surfaces of the board-like, plane pieces of wood are pre-dried prior to the gluing, and actually particularly by heating, preferably by irradiation by means of UV light or infrared radiation. 
Da bi se ovdje produžilo otvoreno vrijeme na jednostavan i učinkovit način, u skladu s jednim ostvarenjem predmetnog izuma, predviđeno je da se površine koje se trebaju zalijepiti ravnog komada od drva koji ima oblik ploče osuše prije nego se zalijepe, i to naročito pomoću zagrijavanja, poželjno zračenjem UV svijetlom ili infracrvenim zračenjem.
The antibody or antigen binding portion thereof of any one of the preceding claims, wherein the antibody isotype is selected from the group consisting of an IgG1, an IgG2, an IgG3, an IgG4, an IgM, an IgA1, an IgA2, an IgAsec, an IgD, and an IgE antibody. 
HR P20170834 T1 (b) njegov dio koji se vezuje za antigen je Fab'2; ili (c) izotip antitijela je odabran od IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgAsec, IgD, i IgE antitijela.
The method of claim 14, wherein the agent for treatment of diabetes is selected from the group consisting of a biguanide (e.g. metformin), a sulfonylurea, a meglitinide or glinide (e.g. nateglinide), a DPP-IV inhibitor, an SGLT2 inhibitor, a glitazone, a different GLP-1 agonist, an insulin, and an insulin analogue. 
Spoj za uporabu prema zahtjevu 22, naznačen time, da: sredstvo za liječenje dijabetesa je bigvanid (primjerice metformin), sulfonilurea, meglitinid ili glinid, poželjno nateglinid, DPP-IV-inhibitor, SGLT2-inhibitor, glitazon, različiti agonist za GLP-1, inzulin ili analog inzulina;
Accordingly, the linker or linkage can be chosen to optimize the pharmacokinetic and/or pharmacodynamic properties of the rapamycin carbohydrate derivative. 
U skladu s time, veznik ili veza može se izabrati tako da se optimiziraju farmakokinetička i/ili farmakodinamička svojstva ugljikohidratnog derivata rapamicina.
mixing the solution resulting from step (iv) with a fat phase in order to obtain the low fat spread. 
(v) miješanje otopine dobivene u koraku (iv) s masnom fazom radi dobivanja namaza s niskim sadržajem masti.
A method for producing a monoclonal antibody which binds to an extracellular domain of human ILT7, comprising the steps of: culturing the antibody producing cell by the method according to claim 7; and recovering the monoclonal antibody from the culture. 
Metoda za proizvodnju monoklonalnog antitijela koje se veže na vanstaničnu domenu humanog ILT7, koja uključuje korake: uzgoja stanice koja proizvodi antitijelo pomoću metode prema zahtjevu 7 i izuzimanje tog monoklonalnog antitijela iz kulture.
Unfortunately, not all patients are responsive and a large number fail this therapy. 
Nažalost, veliki broj pacijenata ne reagira na terapiju.
Those firms which currently recycle PMMA and/or ABS have to live with the problem of contamination by crosslinked PMMA, leading to the discarding of large quantities of material intended for recycling. 
One firme koje danas recikliraju PMMA i/ili ABS moraju živjeti s problemom kontaminacije od umreženih PMMA, što dovodi do bacanja velikih količina materijala koji je namijenjen za recikliranje.
The pharmaceutical composition according to claim 7, wherein at least 90% of the formoterol active agent particles by volume exhibit an optical diameter of 5 µm or less. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 14, naznačen time što najmanje 90% čestica formoterola kao aktivnog sredstva po volumenu pokazuju optički promjer od 5 µm ili manji.
Rifamicin SV, which has been known since the 1960s, is a semi-synthetic active ingredient which is derived from rifamicin S and which has a strong antimicrobial and/or anti-infectious activity both locally and parenterally. 
Rifamicin SV, poznat od 1960-ih, je polusintetički aktivni sastojak nastao od Tifamicina S a koji ima jako antimikrobno iili antiinfektivno djelovanje i lokalno i parenteralno.
In some embodiments, the present teachings provide crystalline compounds of the following structural formula (II): 
Spoj predstavljen slijedećom strukturnom formulom: gdje je barem 50% po masi spoja kristalno.